| Endometrial Cancer |
1 |
1 |
| Breast Cancer |
0 |
0.95 |
| Estrogen Receptor-Positive (ER+) Breast Cancer |
0 |
0.74 |
| Estrogen |
0 |
0.99 |
| Cancer |
0 |
0.66 |
| Colorectal Cancer |
0 |
0.56 |
| Uterine Cancer |
0 |
0.98 |
| Cancer Survivor |
0 |
0.97 |
| Selective Estrogen Receptor Modulators |
0 |
0.43 |
| Vagina |
0 |
0.24 |
| Atrophic Vaginitis |
0 |
0.19 |
| Uterus |
0 |
0.15 |
| Obesity |
0 |
0.11 |
| Adenocarcinoma |
0 |
0.09 |
| Breast |
0 |
0.06 |
| North Carolina |
0 |
0.06 |
| Cardiovascular disease |
0 |
0.03 |
| Cardiovascular Risk Management |
0 |
0.03 |
| Disease Recurrence |
0 |
0.03 |
| Epidemiology |
0 |
0.03 |
| Histology |
0 |
0.03 |
| Hormonal Therapy |
0 |
0.03 |
| Hysterectomy |
0 |
0.03 |
| Menopause |
0 |
0.03 |
| Meta-Analysis |
0 |
0.03 |
| Oophorectomy |
0 |
0.03 |
| Osteoporosis |
0 |
0.03 |
| Patient History |
0 |
0.03 |
| Prognosis |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Skin and Soft Tissue Infection |
0 |
0.03 |
| Surgery |
0 |
0.03 |
| Tissue |
0 |
0.03 |
| Vaginitis |
0 |
0.03 |